Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
| ▸ | ALKBH1 | Q13686 | 6/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23698295 | 0.84 | GPR119 (0.62) | P4HTMALKBH1GPR119 | |
| SCHEMBL24945663 | 0.84 | GPR119 (0.62) | P4HTMALKBH1GPR119 | |
| SCHEMBL21551278 | 0.80 | GPR119 (0.59) | ALKBH1CHRM2CHRM4GPR119CHRM1 | |
| SCHEMBL24945650 | 0.77 | PRMT5 (0.53) | P4HTMALKBH1GPR119KIT | |
| SCHEMBL23698294 | 0.77 | PRMT5 (0.53) | P4HTMALKBH1GPR119KIT | |
| SCHEMBL26086819 | 0.76 | SLC6A7 (0.40) | CHRM2CHRM4CHRM1 | |
| SCHEMBL23730789 | 0.76 | KIT (0.44) | P4HTMALKBH1GPR119KIT | |
| SCHEMBL28539423 | 0.75 | GPR119 (0.78) | CHRM2GPR119CHRM1 | |
| SCHEMBL21564435 | 0.75 | GPR119 (0.78) | CHRM2GPR119CHRM1 | |
| SCHEMBL29614210 | 0.74 | ALKBH1 (0.45) | P4HTMALKBH1GPR119S1PR5KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092022-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2025-03-20 | — | — | US | disclosed |
| EP-4377310-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023010078-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023010078-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092022-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | P4HTM 1310/4885ALKBH1 4548/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.